By Sheeba M. | May 28, 2026
Organigram’s Turnaround Inflection: Why This Canadian LP is Ready for U.S. Expansion
Organigram Holdings (OGI) just signaled a watershed moment for Canadian licensed producers. The company’s May earnings call revealed Q2 revenue of $36.2M (18% QoQ growth), adjusted EBITDA positive for the first time in 6 quarters, and management guidance for U.S. market entry by Q4 2026. For a stock that traded below $0.50 just 18 months ago, this is a legitimate turnaround story.
Here’s what’s changed: Canadian LP margins have finally stabilized as the competitive race ended. Organigram’s cost-of-goods-sold fell to 32% of revenue (down from 47% in 2024), while pricing power in premium flower and edibles improved. The company is now on track to generate $6-8M quarterly adjusted EBITDA by Q1 2027—enough to fund U.S. expansion without external capital.
The U.S. Strategy
Organigram’s U.S. play is elegant: They’re pursuing U.S. hemp-derived cannabinoid products (delta-9, delta-8, THCa) through domestic partners while building relationships with U.S. MSOs for eventual M&A. The hemp strategy lets them enter U.S. distribution immediately (no federal restriction on hemp), build brand recognition, then scale via MSO acquisition when federal legalization accelerates post-election.
Management estimates $40-60M revenue run-rate from U.S. hemp products within 12 months of launch. Combined with $45M+ annual Canadian EBITDA by Q3 2027, Organigram (OGI) becomes a $200M+ market-cap story—vs current $80M.
Valuation Catalyst Timeline
- June 2026: Announce U.S. hemp distribution partnerships (likely 2-3 brands)
- Aug 2026: First U.S. hemp revenue reported; analyst target raises
- Nov 2026: MSO M&A rumors (Organigram is acquisition target for U.S. players)
- Q1 2027: 3-5x stock rerating as earnings visibility improves
Risk Management
Risks: Canadian LP competition intensifies (unlikely given consolidation), U.S. hemp distribution faces regulatory pushback (low probability), or MSO consolidation excludes Organigram (unlikely given balance sheet strength). Entry point: Sub-$1.00 USD per share; upside target: $2.50-3.50 per share within 18 months.
Sources
- Organigram Holdings Inc. — Q2 2026 earnings release and investor presentation
- Seeking Alpha — Canadian LP earnings call transcripts and analysis
- Cannabis Strategic Ventures — U.S. hemp product opportunity sizing
Track cannabis stocks with the Weedstock Real-Time Tracker